Please login to the form below
Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics
Takes up the non-executive role at the AI-focused medical imaging firm
Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of ultromics - an artificial intelligence-focused medical imaging firm.
Mortazavi has 17 years’ experience in UK companies, particularly in the biotechnology investment field and joined London-based biotech Silence Therapeutics in 2012 leading its refinancing business and driving business.
He said: “I am truly excited to be joining the board of ultromics. Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of man plus machine rather than man vs Machine in medical imaging.”
Ultromics - formed in May 2017 - is backed by Oxford Sciences Innovation and the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Mtech Access
We are Mtech Access, a global market access and health economics and outcomes research (HEOR) consultancy supporting top Pharmaceutical companies,...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
